Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • México GPDx
  • Pacientes COVID
  • Solicitar información
  • (55) 2623 0433 Más Información
  • Part of brands: |
GDPx MexicoGDPx Mexico
  • Part of brands: |
  • Te guiamos
    • Fertilidad
    • Prevención de enfermedades hereditarias
    • Embarazo Tranquilo
  • Salud Reproductiva
    • Especialistas
      • ERA
      • Emma
      • ALICE
      • EndomeTRIO
      • PGT-A
      • EMBRACE
      • PGT-M
      • NACE
      • CGT
      • PCR COVID-19
      • SAT
      • POC
    • Pacientes
      • ERA
      • EMMA
      • ALICE
      • EndomeTRIO
      • PGT-A
      • EMBRACE
      • PGT-M
      • NACE
      • CGT
      • SAT
      • POC
  • Diagnóstico
  • Sobre Nosotros
    • Investigación Igenomix
    • Sobre Igenomix
  • Blog
  • COVID-19 WEBINARS
Genomics Precision Diagnostic > Reproductive > Premature Ovarian Insufficiency Precision Panel

Premature Ovarian Insufficiency Precision Panel

Premature Ovarian Insufficiency (POI) also known as premature ovarian failure or premature menopause, is defined as cessation of menstruation before the expected age of menopause.It is a loss of ovarian function before the age of 40 and it is a major cause of female infertility. There is an array of etiologies, including genetic, autoimmune and iatrogenic causes.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Premature Ovarian Insufficiency (POI) also known as premature ovarian failure or premature menopause, is defined as cessation of menstruation before the expected age of menopause.It is a loss of ovarian function before the age of 40 and it is a major cause of female infertility. There is an array of etiologies, including genetic, autoimmune and iatrogenic causes. It is a highly heterogeneous condition presenting with ovarian dysgenesis and primary amenorrhea, or with secondary amenorrhea and it can be associated with other congenital or acquired abnormalities. Since the age of menopause is an inheritable trait, POI has a strong genetic component worth investigating. POI is considered primary when the ovary fails to function normally and secondary if the hypothalamus and pituitary fail to provide appropriate gonadotropin stimulation. POI not only interferes with a woman’s reproductive potential, but it is also associated with an increased risk of osteoporosis, cardiovascular disease and earlier mortality.

  • The Igenomix Premature Ovarian InsufficiencyPrecision Panel can be used to make a directed and accurate differential diagnosis of infertility ultimately leading to a better management of the patient and achieve a healthy baby at home. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

     

Indication

The Igenomix Premature Ovarian Insufficiency Precision Panel is indicated for those patients with clinical suspicion or diagnosis with or without the following manifestations:

  • Signs of Turner syndrome: short stature, webbed neck, shieldlike chest etc 
  • Thyroid involvement: goiter, exophthalmos, bradycardia or tachycardia
  • Adrenal insufficiency: orthostatic hypotension, hyperpigmentation, hypotension, decreased axillary and pubic hair  
  • Autoimmunity: vitiligo, nail dystrophy, mucocutaneous candidiasis, alopecia areata etc 
  • Hypoestrogenism: atrophic vaginitis, hot flashes, night sweats, vaginal dryness, irritability, decreased sexual desire
  • Enlarged ovaries

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team for an initial consultation, workup and assisted reproductive technologies (ART), replacement hormonal therapy (RHT), and prevention of complications associated with multiorgan involvement
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance.

Genes & Diseases

Methodology

References

See scientific referrals

Qin, Y., Jiao, X., Simpson, J. L., & Chen, Z. J. (2015). Genetics of primary ovarian insufficiency: new developments and opportunities. Human reproductionupdate, 21(6), 787–808. https://doi.org/10.1093/humupd/dmv036

Laven J. S. (2016). Primary Ovarian Insufficiency. Seminars in reproductive medicine, 34(4), 230–234. https://doi.org/10.1055/s-0036-1585402

Rossetti, R., Ferrari, I., Bonomi, M., &Persani, L. (2017). Genetics of primary ovarian insufficiency. Clinicalgenetics, 91(2), 183–198. https://doi.org/10.1111/cge.12921

Bilgin, E. M., &Kovanci, E. (2015). Genetics of premature ovarian failure. Currentopinion in obstetrics&gynecology, 27(3), 167–174. https://doi.org/10.1097/GCO.0000000000000177

Hewlett, M., &Mahalingaiah, S. (2015). Update on primary ovarian insufficiency. CurrentOpinion In Endocrinology, Diabetes And Obesity, 22(6), 483-489. doi: 10.1097/med.0000000000000206

Anasti, J. (1998). Premature ovarian failure: an update. Fertility And Sterility, 70(1), 1-15. doi: 10.1016/s0015-0282(98)00099-5

Vujovic, S., Ivovic, M., Tancic-Gajic, M., Marina, L., Barac, M., &Arizanovic, Z. et al. (2012). Premature ovarian failure. SrpskiArhiv Za CelokupnoLekarstvo, 140(11-12), 806-811. doi: 10.2298/sarh1212806v

Shelling A. N. (2010). Premature ovarian failure. Reproduction (Cambridge, England), 140(5), 633–641. https://doi.org/10.1530/REP-09-0567

Touraine P. (2020). Premature ovarian insufficiency: step-by-step genetics bring new insights. Fertility and sterility, 113(4), 767–768. https://doi.org/10.1016/j.fertnstert.2019.12.032

FOLLETO

ERA
Descargar

Request Information

Igenomix

TE GUIAMOS

Fertilidad
Prevención de enfermedades hereditarias
Embarazo Tranquilo

SERVICIOS

Soluciones genéticas
Aprende sobre genética

SOBRE IGENOMIX

Sobre Igenomix
Contacto
Press and news
Trabaja con nosotros

SÍGUENOS

Blog: Camino a la fertilidad

  (55) 2623 0433
  Escríbenos
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
País

[2019] © Igenomix Política de privacidadPolítica de calidadNota legal Política de cookies

Solicitar Información

  • Pacientes COVID
  • Te guiamos
    • Fertilidad
    • Prevención de enfermedades hereditarias
    • Embarazo Tranquilo
  • Salud Reproductiva
    • Especialistas
      • ERA
      • Emma
      • ALICE
      • EndomeTRIO
      • PGT-A
      • EMBRACE
      • PGT-M
      • NACE
      • CGT
      • PCR COVID-19
      • SAT
      • POC
    • Pacientes
      • ERA
      • EMMA
      • ALICE
      • EndomeTRIO
      • PGT-A
      • EMBRACE
      • PGT-M
      • NACE
      • CGT
      • SAT
      • POC
  • Diagnóstico
  • Sobre Nosotros
    • Investigación Igenomix
    • Sobre Igenomix
  • Blog
  • COVID-19 WEBINARS
  • México GPDx
  • Solicitar información
  • Part of brands: |